OVERVIEW

New Therapies for Type 2 Diabetes is organized by The Ohio State Center for Continuing Medical Education (OSUCCME).

Event Dates: 02/01/2019 - 02/01/2022

Accreditation:
AMA Credit Designation Statement
The Ohio State University Center for Continuing Medical Education (CCME) designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
Today on MedNet21, we're going to discuss New Therapies for Type 2 Diabetes.

Insulin has been used for almost 100 years and non-insulin diabetes medications since 1946, but over the last few years there have been a flurry of new therapies. These new medications have focused on two main targets: 1) reducing hypoglycemia and 2) decreasing cardiovascular disease, the leading cause of mortality in type 2 diabetes

Objective(s):
As a result of this educational activity, webcast participants will be able to: DESCRIBE the role of new medical therapies in hypoglycemia; and DESCRIBE the role of new medical therapies in cardiovascular disease. You’ll also learn about the following:
• New directions in the treatment of type 2 diabetes
• Hemoglobin A1C targets
• Treatment of type 2 diabetes when medication cost is a consideration
• New glucose monitoring technologies.

Additional details will be posted as soon as information is available.